Prognostic significance and predictors of pathological response following neoadjuvant paclitaxel, carboplatin, and cetuximab therapy in head and neck squamous cell carcinoma.
INTRODUCTION Neoadjuvant chemotherapy using paclitaxel, carboplatin, and cetuximab (PCE-NAC) is used in patients with locally advanced head and neck squamous cell carcinoma (HNSCC); however, predictors of survival outcome remain unclear. This study aimed to evaluate the prognostic value of the pathological response to...